NBIX: Neurocrine Biosciences, Inc. - Summary | Jitta

Neurocrine Biosciences, Inc.

NASDAQ:NBIX

Price
$130.65
Loss Chance
45.2%
6.52JITTA SCORE
113.56%Over Jitta Line
Jitta Ranking
59 / 1,129
796 / 4,931
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (69)
Recent Business Performance (97)
Financial Strength (84)
Return to Shareholders (45)
Competitive Advantage (81)
Jitta Signs
Revenue and EarningConsistent High Growth in the past 5 years
Recent Business PerformanceEarning Growth Last Year
Debt LevelLow Long Term Debt
Return on EquityConsistently High
CapExVery Low
Interest Coverage RatioVery Good
Cash Conversion CycleLess than 60 days
Operating MarginInconsistent
Key Stats
Jitta Score
Jitta Line
6.52
113.56%
1.31
153.46%
2.06
253.04%
Biotechnology
4.95
137.32%
5.23
534.05%
5.18
167.82%
COMPANY DESCRIPTION
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL – Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.